Menopause Supplements

TINA.org sent letters to 100 menopause supplement companies notifying each of them of a deceptive marketing trend that is prevalent in the industry (e.g., marketing supplements as able to treat a variety of menopausal symptoms without the necessary scientific substantiation required by the FTC or the required FDA approval) and urging each of them to review their marketing to ensure it complies with the law.

In addition, TINA.org investigated and filed regulatory complaints against two menopause supplement brands, Pharmavite’s Equelle and Alliance Pharmaceuticals’ Amberen.


Timeline

2024
October 7

TINA.org sends letters to 100 menopause supplement companies notifying them of a deceptive marketing trend in the industry and urging them to review their marketing to ensure compliance with the law.

36 of those 100 companies previously received an FTC Notice of Penalty Offenses Concerning Substantiation in April 2023. Regarding the 64 that did not receive such a notice, TINA.org sent a letter to the FTC urging it to send a notice to those companies in order to help efficiently address deception in this industry.


Featured


The Latest

Filters


Class-Action Tracker

i-Cool for Menopause

Class Action

i-Cool for Menopause

In December 2015, a state judge preliminarily approved a settlement of a false advertising class-action lawsuit against DSM Nutritional Products. The complaint, which was originally filed in 2011, alleges that…